Neovacs And Lupus Europe Join Voices On World Lupus Day
May 10 2017 - 1:31AM
NEOVACS AND LUPUS
EUROPE JOIN VOICES ON WORLD LUPUS DAY
In order to raise
awareness about lupus, the progress made in the development of new
treatments, and the importance of clinical trials for
patients
Paris and Boston,
May 10th 2017 -
Neovacs (Alternext Paris: ALNEV), a leader in
active immunotherapies for the treatment of autoimmune diseases,
and Lupus Europe, umbrella association of
currently 24 national lupus patient organisations from 22 member
countries throughout Europe, together join voices on the occasion
of World Lupus Day in order to raise awareness
about this chronic and debilitating autoimmune disease - whose
origin is still poorly understood by the general population, but
also decision makers.
Lupus affects numerous organs and
tissues, producing heterogeneous clinical signs (skin rash,
arthritis, photosensitivity, renal damage, neurological disorders,
anaemia.), which vary from one person to another and change as the
disease progresses with periods of remissions and relapses or
flares. Lupus affects mostly women (9 women for 1 man). All over
Europe, up to 500,000 people are affected with different grades of
severity.[1]
Fortunately, they can count on
patient associations to accompany them on their path with the
disease. Lupus Europe gathers those
organisations in order to better support people living with lupus
all around Europe, help them understand their condition, and better
improve research and scientific knowledge of the disease.
One of these scientific actors,
Neovacs, is a specialist in active
immunotherapy, dedicated to developing therapeutic vaccines for the
treatment of autoimmune diseases such as lupus. Unlike monoclonal
antibodies used in many cancer treatments and inflammatory diseases
treatments, Kinoid® therapeutic vaccines developed by Neovacs induce the patients' immune system to produce
their own polyclonal antibodies. Recent researches highlighted the
major role of IFNalpha in the immune system dysfunction associated
with lupus, opening new perspectives for the treatment of this
condition. IFNalpha Kinoid is the most advanced product produced by
Neovacs. This vaccine is currently in phase
IIb in lupus indication, which is hopeful for patients whose
participation in clinical trials are crucial to help scientists
discover new treatments.
"50 years ago,
lupus meant a death sentence. Today, people can have a relatively
normal life, thanks to more - but not yet enough - treatments and a
better understanding of the disease. It's the clinical trials that
are vital to lupus. In terms of research, we are quite excited
about a few labs who have taken interest into lupus these past few
years. We are watching with great interest the possibility of a
vaccination, which would be magnificent for the patients",
explains Anne Charlet, Vice Chair of the Lupus
Europe association.
About
Neovacs
Listed on Alternext Paris since 2010, Neovacs is today a leading
biotechnology company focused on an active immunotherapy technology
platform (Kinoids) with applications in autoimmune and/or
inflammatory diseases. On the basis of the company's proprietary
technology for inducing a polyclonal immune response (covered by
five patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNalpha-Kinoid, an
immunotherapy being developed for the indication of lupus and
dermatomyositis. Neovacs is also conducting preclinical development
works on other therapeutic vaccines in the fields of auto-immune
diseases, oncology, allergies and Type 1 diabetes. The goal of the
Kinoid approach is to enable patients to have access to safe
treatments with efficacy that is sustained in these life-long
diseases. www.neovacs.fr
About Lupus
Europe
LUPUS EUROPE is the umbrella association of currently 24 national
lupus patient organisations from 22 member countries throughout
Europe. It is a registered charity supporting people with lupus in
Europe,s keeping member countries informed
by blog, Facebook, Twitter, and
regular NewsFlashes on the work of LUPUS EUROPE,
promoting lupus at conventions and meetings throughout
Europe.
Its mission is to:
-
make lupus a well-known illness throughout
Europe and, in partnership with the medical profession, secure high
quality standards of treatment and support for people with lupus,
their families and their care
-
encourage and support the health and social
systems of member countries, to allow people with lupus to live
independent lives and be recognised as equal member of
society.
http://lupus-europe.eu/
Contacts
NEOVACS - Corporate Communication & Investor
Relations
Charlène Masson
+33 (0)1 53 10 93 14
cmasson@neovacs.com
NEWCAP - Press
Relations
Annie-Florence Loyer
+ 33 (0)1 44 71 00 12 //
+ 33 (0)6 88 20 35 59
afloyer@newcap.fr
Lupus Europe
secretariat@lupus-europe.org
[1]
Cervera R, Khamashta MA, Hughes GR. The Euro-lupus project:
epidemiology of systemic lupus erythematosus in Europe. Lupus 2009;
18: 869-74.
Carter EE, Barr SG, Clarke AE. The global burden of SLE:
prevalence, health disparities and socioeconomic impact. Nature
reviews. Rheumatology 2016: 12(10): 605-620.
PDF version
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: NEOVACS via Globenewswire
Neovacs (EU:ALNEV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Neovacs (EU:ALNEV)
Historical Stock Chart
From Jul 2023 to Jul 2024